Biotech Values

[DewDiligence]

Re: VVUS, BPA:

>> I did see BPA. ceo made an interesting comment about vvus whom he doesn't seem so worried about. <<

I meant to ask you about this but forgot. What exactly did Mr. Simes say about VVUS? T.i.a.

--
VVUS up on testosterone drug study:

[VVUS is competing with BPA, CLGY, and PG in the female HSDD market.]

http://tinyurl.com/6m4eo

>>
By Laura Gilcrest
CBS MarketWatch
5:03 PM ET Nov. 16, 2004

WASHINGTON (CBS.MW) -- Vivus shares jumped more than 7 percent Tuesday after the Mountain View, Calif.-based firm announced it had completed a Phase 2 study of Testosterone MDTS to treat female sexual dysfunction.

The metered-dose transdermal spray therapy is intended as treatment for Hypoactive Sexual Desire Disorder, a condition that Vivus said affects about 25 percent of women. Vivus shares shot up 7.11 percent in Tuesday trading, closing at $6.18.

Testosterone MDTS delivers a preset dose of testosterone to the skin where it is released into the bloodstream over 24 hours, the company said.

Vivus said it would release in the first quarter of 2005 the results of the six-month, placebo-based Phase 2 study involving 260 women.

The clinical trial is being conducted in Australia by Acrux Limited, which licenses the technology to Vivus.
<<